CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,714 | +23.8% | 5,528 | +96.5% | 0.00% | – |
| Q2 2023 | $10,267 | +71.1% | 2,813 | -3.2% | 0.00% | – |
| Q3 2022 | $6,000 | -53.8% | 2,906 | -47.4% | 0.00% | – |
| Q2 2022 | $13,000 | -18.8% | 5,522 | +68.7% | 0.00% | – |
| Q1 2022 | $16,000 | -40.7% | 3,273 | +37.9% | 0.00% | – |
| Q4 2021 | $27,000 | -34.1% | 2,373 | -14.9% | 0.00% | -100.0% |
| Q3 2021 | $41,000 | -31.7% | 2,787 | -45.7% | 0.00% | -50.0% |
| Q2 2021 | $60,000 | +275.0% | 5,131 | +299.0% | 0.00% | – |
| Q1 2021 | $16,000 | -61.9% | 1,286 | -61.6% | 0.00% | -100.0% |
| Q4 2020 | $42,000 | +133.3% | 3,349 | +183.6% | 0.00% | – |
| Q3 2020 | $18,000 | -90.4% | 1,181 | -84.6% | 0.00% | -100.0% |
| Q2 2020 | $188,000 | +4600.0% | 7,650 | +1426.9% | 0.01% | – |
| Q3 2019 | $4,000 | -75.0% | 501 | -75.7% | 0.00% | -100.0% |
| Q1 2019 | $16,000 | -84.3% | 2,065 | -90.5% | 0.00% | -85.7% |
| Q4 2018 | $102,000 | +175.7% | 21,641 | +430.5% | 0.01% | +133.3% |
| Q3 2018 | $37,000 | +825.0% | 4,079 | +1136.1% | 0.00% | – |
| Q2 2018 | $4,000 | -33.3% | 330 | -20.1% | 0.00% | -100.0% |
| Q1 2018 | $6,000 | – | 413 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 1,510,282 | $7,370,000 | 4.76% |
| SANDERS MORRIS HARRIS LLC | 873,021 | $4,261,000 | 0.83% |
| P.A.W. CAPITAL CORP | 150,000 | $732,000 | 0.76% |
| Nantahala Capital Management | 2,244,359 | $10,952,000 | 0.48% |
| Bleichroeder LP | 552,000 | $2,694,000 | 0.48% |
| APOGEM CAPITAL LLC | 111,259 | $543,000 | 0.37% |
| Slate Path Capital LP | 1,483,619 | $7,240,000 | 0.37% |
| Robertson Stephens Wealth Management, LLC | 478,500 | $2,335,000 | 0.20% |
| CARLSON CAPITAL L P | 405,000 | $1,976,000 | 0.14% |
| Bridgefront Capital, LLC | 19,968 | $97,000 | 0.12% |